Responses
Poster Presentations
SLE, Sjögren's and APS - treatment
SAT0249 Safety, pharmacokinetics, pharmacodynamics and inhibition of T-cell dependent antibody response (TDAR) with MEDI4920, a novel, engineered CD40 ligand (CD40L) antagonist: results of a first-time-in-human study
Compose a Response to This Article
Other responses
No responses have been published for this article.